The composite success
|
|
- Rhoda Robinson
- 5 years ago
- Views:
Transcription
1 The composite success Comparing drug development strategies with probabilities of success including benefit-risk assessment to inform decision-making Gaëlle Saint-Hilary 1 Véronique Robert 2, Mauro Gasparini 1 1 Politecnico Di Torino (Italy) 2 Institut de Recherches Internationales Servier (France) gaelle.sainthilary@polito.it PSI Conference, 15 May 2017 Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
2 Outline Introduction Predictive probability of success Composite definition of success Statistical significance Clinical relevance Positive benefit-risk balance Example in Major Depressive Disorders Conclusion Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
3 Introduction Decision-making problem Given what has been observed already, what are the chances of success of the drug development? We can calculate the Predictive Probability of Success (PPoS)... but what is a success? Usually defined as a statistically significant result (O'Hagan 2005, Gasparini 2013) Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
4 Introduction The success of a drug development The success of a drug development is driven by the conjunction between a valuable product and a successful development strategy A Marketing Authorization is usually conditioned by the success of the pivotal clinical trials, which must Reach statistical significance on their primary endpoint While showing a clinically meaningful effect of the drug The benefit-risk balance is a strong predictor of the long-term viability of a medicine, and a key element for the regulatory approval process Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
5 Introduction Composite definition of success We define the success of a drug development strategy as the simultaneous fulfillment of the following criteria in all pivotal trials: The statistical significance on the primary efficacy criterion A clinically meaningful effect on the primary efficacy criterion A positive benefit-risk balance versus the comparator(s) Given what has been observed already, what are the chances of success of the drug development? Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
6 Predictive Probability of Success (PPoS) Example: Success = statistical significance on the primary efficacy criterion δ=difference between treatments y m=observations in trial m d m=sample estimate of δ in trial m f =probability distribution Success of trial m: d m > c, c > 0 critical value PPoS = P(d m > c) = f (d m δ) f (δ y 1,..., y m 1 )dzdδ d m>c Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
7 Predictive Probability of Success (PPoS) Example for a Normal distribution After Trial 1, Predictions for Trial 2 Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
8 Predictive Probability of Success (PPoS) Example for a Normal distribution After Trial 1, Predictions for Trial 2 Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
9 Composite definition of success 1. Statistical significance on the primary endpoint Consider 2 treatments (i = 1, 2) assessed on the primary efficacy criterion, noted criterion 1 Criterion performance ξ i1 : performance of treatment i on criterion 1 Difference between treatments δ = ξ 11 ξ 21 Sample estimate in the considered trial d = sample estimate of δ Statistical significance The null hypothesis H 0 : δ 0 is rejected at level α if d > c, for c > 0 some critical value Clinical relevance The treatment effect is clinically meaningful if d > d T, for d T > 0 some clinical threshold Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
10 Composite definition of success 2. Clinical relevance on the primary endpoint Consider 2 treatments (i = 1, 2) assessed on the primary efficacy criterion, noted criterion 1 Criterion performance ξ i1 : performance of treatment i on criterion 1 Difference between treatments δ = ξ 11 ξ 21 Sample estimate in the considered trial d = sample estimate of δ Statistical significance The null hypothesis H 0 : δ 0 is rejected at level α if d > c, for c > 0 some critical value Clinical relevance The treatment effect is clinically meaningful if d > d T, for d T > 0 some clinical threshold Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
11 Composite definition of success 3. Positive benefit-risk balance Probabilistic Multi-Criteria Decision Analysis (pmcda) Waddingham 2016 ξ ij performance of treatment i on criterion j u j () used to normalize the performances on the criteria by mapping them on a 0 to 1 scale MCDA is identified by the EMA as the most comprehensive among the quantitative methodologies w j reflects the importance of the criteria u(ξ i, w) = w 1 u 1 (ξ i1 ) w n u n (ξ in ) Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
12 Composite definition of success 3. Positive benefit-risk balance Consider 2 treatments (i = 1, 2) assessed on n criteria (j = 1,..., n) of benefit and risk Benefit-risk utility score u(ξ i, w) = w 1 u 1 (ξ i1 ) w n u n (ξ in ) = n j=n w ju j (ξ ij ) Difference in benefit-risk utility scores u(ξ 1, ξ 2, w) = u(ξ 1, w) u(ξ 2, w) Sample estimate in the considered trial u(x 1, x 2, w) where x 1 and x 2 are sample estimates of ξ 1 and ξ 2 Positive benefit-risk balance Treatment 1 has a positive benefit-risk balance versus treatment 2 if u(x 1, x 2, w) > 0 Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
13 Predictive Probability of the Composite Success and of its components Predictive probabilities in one future trial comparing two treatments: Statistical significance on the primary efficacy criterion PPoS 1 = P(d > c) c > 0 critical value Clinically meaningful effect on the primary efficacy criterion PPoS 2 = P(d > d T ) d T > 0 clinical threshold Positive benefit-risk balance versus the comparator PPoS 3 = P( u(x 1, x 2, w) > 0) Predictive probability of composite success PPoS = P [(d > c) (d > d T ) ( u(x 1, x 2, w) > 0)] d, x 1, x 2 sample estimates of δ, ξ 1, ξ 2 in the future trial Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
14 Predictive Probability of the Composite Success and of its components Predictive probabilities in several future trials comparing two treatments: Statistical significance on the primary efficacy criterion PPoS 1 = ( ) S m=1 P [d m > c m δ] f (δ y)dδ c m critical value in trial m Clinically meaningful effect on the primary efficacy criterion PPoS 2 = ( ) S m=1 P [d m > dt m δ] f (δ y)dδ dt m clinical threshold in trial m Positive benefit-risk balance versus the comparator PPoS 3 = ( ) S m=1 P [ u(xm 1, x m 2, w) > 0 ξ 1, ξ 2 ] f (ξ 1 x 1 )f (ξ 2 x 2 )dξ 1 dξ 2 Predictive probability of composite success PPoS = ( ) S m=1 P [(d m > max(c m, dt m )) ( u(x m 1, x m 2, w) > 0) δ, ξ 1, ξ 2 ]. f (δ, ξ 1, ξ 2 y, x 1, x 2 )d (δ, ξ 1, ξ 2 ) d m, x m 1, x m 2 sample estimates of δ, ξ 1, ξ 2 in trial m Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
15 Example in Major Depressive Disorders Fictive case-study Effective treatment Dose-response relationship for efficacy and safety Hypokalemia may be a serious adverse effect Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
16 Example in Major Depressive Disorders Fictive case-study First strategy assessment: which dose has the best chances to succeed in Phase III? Predictive distributions Dose PPoS 1 PPoS 2 PPoS 3 PPoS (stat. signif.) (clin. relev.) (positive B/R) (composite) Low dose 74% 48% 88% 48% High dose 93% 78% 24% 24% Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
17 Example in Major Depressive Disorders Fictive case-study Strategy refinement: is it better to optimize the efficacy of the Low dose or to manage the risks for the High dose? Low dose with a possible dose-increase for non-responders High dose with potassium supplementation to prevent Hypokalemia Predictive distributions Regimen PPoS 1 PPoS 2 PPoS 3 PPoS (stat. signif.) (clin. relev.) (positive B/R) (composite) High dose suppl 93% 78% 95% 78% Dose increase 83% 59% 69% 58% Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
18 Concluding remarks The predictive probability of composite success and its components are helpful tools to compare development strategies and to inform decision-making in the pharmaceutical development Evidence-based approach Clinical data should be available: may not be appropriate in very early development Previous and future trials should be done in the same context (endpoint, duration, population) New hypotheses could be combined with the available evidence using priors What is a good PPoS? Phase/disease/project/team dependent Low amount of evidence PPoS close to 50% Uncertainty to take a decision Bayesian framework: PPoS are updated with the accumulation of knowledge from trial to trial Composite success criteria must be satisfied in each pivotal trial Consistent with the demand of replicability of the results But a similar approach could be applied at the development level (e.g. using meta-analyses) Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
19 Thank-you! Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
20 Main references I Gasparini M, Di Scala L, Bretz F, and Racine-Poon A. Predictive probability of success in clinical drug development. Epidemiology Biostatistics and Public Health, 10-1:e , Waddingham E, Mt-Isa S, Nixon R, and Ashby D. A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment. Biometrical Journal, 58:28 42, OHagan A, Stevens JW, and Campbell MJ. Assurance in clinical trial design. Pharmaceutical Statistics, 4: , Saint-Hilary G, Cadour S, Robert V, and Gasparini M. A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a dirichlet distribution in benefitrisk assessment. Biometrical Journal, 59(3): , Spiegelhalter DJ, Abrams KR, and Myles JP. Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons Ltd, Chichester, UK, Chuang-Stein C, Kirby S, French J, Kowalski K, Marshall S, Smith MK, Bycott P, and Beltangady MA. Quantitative approach for making go/no-go decisions in drug development. Drug Information Journal, 45: , Stallard N, Whitehead J, and Cleall S. Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics, 4: , Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
21 Main references II Zhang J and Zhang JJ. Joint probability of statistical success of multiple phase III trials. Pharmaceutical Statistics, 12: , Wang M, Liu GF, and Schindler J. Evaluation of program success for programs with multiple trials in binary outcomes. Pharmaceutical Statistics, 14: , Hong S and Shi L. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint. Statistics in Medicine, 31: , Ashby D and Smith A. Evidence-based medicine as Bayesian decision-making. Statistics in Medicine, 19: , EMA. Benefit-risk methodology project. work package 4 report: Benefit-risk tools and processes IMI PROTECT. IMI PROTECT Work package 5: Benefit-risk integration and representation Mt-Isa S, Ouwens M, Robert V, Gebel M, Schacht A, and Hirsch I. Structured benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies. Pharmaceutical Statististics, 15: , Antonijevic Z. Optimization of Pharmaceutical R & D Programs and Portfolios. Springer International Publishing, Switzerland, Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
22 Back-up slides Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
23 Example in Major Depressive Disorders Fictive case-study Distributions of the parameters Parameter Sample estimate Prior Likelihood Posterior HAM-D 17 mean total score in each arm (i = 1,..., 3) ( ξ i1 m i N(0, σ0 2) N(ξ i1, σi 2) N σ0 2 m i, HAM-D 17 mean total score, difference versus placebo (i = 1, 2 ) δ i = ξ 31 ξ i1 d i = m 3 m i N(0, s 2 0 ) N(δ i, s 2 i ) N ( σ 2 0 +σ2 i σ 2 0 σ2 i σ 2 0 +σ2 i Occurrence of adverse events in each arm (i = 1,..., 3 ; j = 2,..., 6) ξ ij r ij /n ij Beta(1, 1) Bin(n ij, ξ ij )/n ij Beta(r ij + 1, n ij r ij + 1) σ 2 0 = 104 ; s 2 0 = 2 σ2 0 = s 2 0 s 2 0 +s2 i d i, s 2 0 s2 i s 2 0 +s2 i ) ) Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
24 Example in Major Depressive Disorders Fictive case-study Strategy refinement The two new strategies and their statistical assumptions are as follows: (i) High dose with potassium supplements. The predictions are based on the posterior distribution of ξ 32 obtained for the placebo for Hypokalemia, and on the posterior distributions obtained for the High dose for all the other criteria. (ii) Dose increase. According to the clinicians, 30% to 40% of the patients would increase to the High dose in the Phase III study, therefore a new parameter with a uniform distribution ζ U[0.3, 0.4] is introduced in the model as the proportion of patients receiving the High dose. The distributions of the parameters associated to the efficacy and safety criteria are obtained from the distributions of the initial parameters: (1 ζ) ξ 1j + ζ ξ 2j for j = 1,..., 6. Gaëlle Saint-Hilary (PoliTo & Servier) Decision-making - Composite success 15 May / 24
Adaptive Design for Clinical Trials
Adaptive Design for Clinical Trials Mark Chang Millennium Pharmaceuticals, Inc., Cambridge, MA 02139,USA (e-mail: Mark.Chang@Statisticians.org) Abstract. Adaptive design is a trial design that allows modifications
More informationDisclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA
On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer
More informationKey multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials
Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials Mohammad F. Huque, Ph.D. Office of Biostatistics OTS, CDER/FDA DIA Annual Meeting, Boston,
More informationThe rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation
The rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation Richard Nixon, Modeling and Simulation, Novartis PSI journal club, 2010 March 24 1 Bayesian clinical
More informationModeling and Simulation for Dose Selection using Adaptive Designs
Modeling and Simulation for Dose Selection using Adaptive Designs Nitin Patel Chairman and C.T.O. Cytel, Inc. Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationLeveraging adult data in pediatric product development: The role of Bayesian statistics
Leveraging adult data in pediatric product development: The role of Bayesian statistics Freda W. Cooner, Ph.D. FDA/CDER FDA-University of Maryland CERSI Workshop June 1, 2016 FDA Disclaimer This presentation
More informationIncluding Real World Evidence (RWE) in network meta-analysis
Including Real World Evidence (RWE) in network meta-analysis David Jenkins, Reynaldo Martina, Sylwia Bujkiewicz, Pascale Dequen & Keith Abrams Department of Health Sciences, Background GetReal is a three-year
More informationBayesian Designs for Clinical Trials in Early Drug Development
Vol. 3, No. 6, June 007 Can You Handle the Truth? Bayesian Designs for Clinical Trials in Early Drug Development By St. Clare Chung and Miklos Schulz Introduction A clinical trial is designed to answer
More informationRegulatory Perspective on the Value of Bayesian Methods
American Course on Drug Development and Regulatory Sciences Substantial Evidence in 21st Century Regulatory Science Borrowing Strength from Accumulating Data April 21, 2016 Regulatory Perspective on the
More informationSession 302, JSM 2013: Key Subgroup Analysis Issues in Clinical Trials, Discussion
Session 302, JSM 2013: Key Subgroup Analysis Issues in Clinical Trials, Discussion Olga Marchenko CSDD, Innovation Copyright 2013 Quintiles Ilya Lipkovich, Overview of Subgroup Identification Approaches
More informationPage 78
A Case Study for Radiation Therapy Dose Finding Utilizing Bayesian Sequential Trial Design Author s Details: (1) Fuyu Song and (2)(3) Shein-Chung Chow 1 Peking University Clinical Research Institute, Peking
More information(Draft) Guideline on multiplicity issues in clinical trials
www.pei.de (Draft) Guideline on multiplicity issues in clinical trials Forum Biomedizinische Arzneimittel 14.06.2017 The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health. Statistical
More informationBayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge. J. Jack Lee, Ph.D. Professor, Department of Biostatistics
Bayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge J. Jack Lee, Ph.D. Professor, Department of Biostatistics Nothing to disclose. Disclosure How Do We Bring Theory to Practice
More informationApplication of Modeling and Simulation to Support Clinical Drug Development Decisions in Alzheimer's Disease
Application of Modeling and Simulation to Support Clinical Drug Development Decisions in Alzheimer's Disease Marc R. Gastonguay, Ph.D. Scientific Director, Metrum Institute marcg@metruminstitute.org President
More informationTranslational Update of Probability of Success in Drug Development
Translational Update of Probability of Success in Drug Development Francois Vandenhende, Ph.D. Chairman and Executive Consultant, ClinBAY Invited Lecturer, Institute of Statistics, UCL, Belgium francois@clinbay.com
More informationData Sharing and Models in Pre(Non)- Competitive Space in Addressing Unmet Medical Needs. Critical Path Institute s Alzheimers Drug Development Tool
Data Sharing and Models in Pre(Non)- Competitive Space in Addressing Unmet Medical Needs Critical Path Institute s Alzheimers Drug Development Tool Vikram Sinha, PhD Director, Division of Pharmacometrics
More informationOptimal design of multi-arm multi-stage (MAMS) clinical trials. James Wason, Thomas Jaki
Optimal design of multi-arm multi-stage (MAMS) clinical trials James Wason, Thomas Jaki Introduction - multi-arm trials In some therapeutic areas, there may be several possible agents/treatments awaiting
More informationEuropean Research Projects on Statistical Methodology to Enhance Clinical Trial Designs and Analysis
European Research Projects on Statistical Methodology to Enhance Clinical Trial Designs and Analysis Martin Posch and Franz König Medical University of Vienna www.meduniwien.ac.at/medstat Medical University
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds
More informationSEARS: A Seamless Dose Escalation/Expansion with Adaptive Randomization Scheme
SEARS: A Seamless Dose Escalation/Expansion with Adaptive Randomization Scheme Haitao Pan 1,2, Fang Xie 4, Ping Liu 5, Jielai Xia 1,, Yuan Ji 3, March 7, 2012 1 Department of Health Statistics, Fourth
More informationBayesian analysis for small sample size trials using informative priors derived from historical data
EFSPI & BBS Small populations and level of evidence Bayesian analysis for small sample size trials using informative priors derived from historical data /////////// Andreas Kaiser Bayer AG, Pharmaceuticals
More informationSome key multiplicity questions on primary and secondary endpoints of RCCTs and possible answers
Some key multiplicity questions on primary and secondary endpoints of RCCTs and possible answers Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA Basel Statistical Society,
More informationOncology New Drug Development. Tomoyuki Kakizume Novartis Pharma K.K. Oncology Biometrics and Data Management Dept.
Novartis: Challenging to Accelerate Oncology New Drug Development Tomoyuki Kakizume Novartis Pharma K.K. Oncology Biometrics and Data Management Dept. Bayesian Clinical Trials in Novartis Oncology Phase
More informationAn Overview of Bayesian Adaptive Clinical Trial Design
An Overview of Bayesian Adaptive Clinical Trial Design Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical
More informationStatistics for Decision Processes - Transitions between Research and Development Phases
Statistics for Decision Processes - Transitions between Research and Development Phases PSI Scientific Meeting, March 30 th, 2017/ Richardus Vonk, Head of Research and Clinical Sciences Statistics Disclaimer
More informationThe Plan of Enrichment Designs for Dealing with High Placebo Response
The Plan of Enrichment Designs for Dealing with High Placebo Response Xiangmin Zhang Division of Biometrics I/OB/OTS/CDER/FDA Joint work with Dr. Yeh-Fong Chen (FDA) and Prof. Roy Tamura (University of
More informationField trial with veterinary vaccine
١ Field trial with veterinary vaccine Saeedeh Forghani,, M.D. Clinical Trial and Ethics Department Human Health Management Deputy of Quality Assurance 89/4/2 ٢ ٣ Introduction: The efficacy and safety shall
More informationdecide: A dual target method for setting Go/No-Go criteria
decide: A dual target method for setting Go/No-Go criteria Pat Mitchell Statistical Science Director ECB AstraZeneca Dual target methods for Go/No-Go decision making 19OCT2017 GNGs minimize time spent
More informationSafety Monitoring and Evaluation in Late Phase Clinical Development: An Application in OA Pain
Safety Monitoring and Evaluation in Late Phase Clinical Development: An Application in OA Pain José Pinheiro, Janssen R&D Joint work with Camille Orman, Steven Wang, and Elena Polverejan Janssen R&D Trends
More informationSession 2 summary Designs & Methods. Pairwise comparisons approach. Dose finding approaches discussed: Guiding principles for good dose selection
Session 2 summary Designs & Methods Pairwise comparisons approach Dose finding approaches discussed: PK/PD Modeling (Adaptive) MCPMod Model Averaging Bayesian Adaptive Dose Ranging Emax Dose Response Model
More informationDesigning a Cost-effective Dose-finding Phase 2 Trial with Adaptive Design
Designing a Cost-effective Dose-finding Phase 2 Trial with Adaptive Design Key Concepts of a Cost-effective Adaptive Design Incorporating evaluation of efficacy and safety (tolerability) Dose-Response
More informationStatistical modelling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation
Statistical modelling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation Margaret Gamalo-Siebers, PhD Global Statistical Sciences, Eli Lilly & Co. Statisticians
More informationSession 4: Statistical considerations in confirmatory clinical trials II
Session 4: Statistical considerations in confirmatory clinical trials II Agenda Interim analysis data monitoring committees group sequential designs Adaptive designs sample size re-estimation Phase II/III
More informationReflection paper on the use of extrapolation in the development of medicines for paediatrics
1 2 3 9 October 2017 EMA/199678/2016 4 5 6 Reflection paper on the use of extrapolation in the development of medicines for paediatrics Draft Draft agreed by Biostatistics Working Party September 2017
More informationExperience with Adaptive Dose-Ranging Studies in Early Clinical Development
Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Judith Quinlan MSc Vice President Adaptive Trials Cytel Inc. judith.quinlan@cytel.com Thanks to members of the PhRMA Adaptive
More informationEisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency
Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency This is not an official PMDA guidance or policy statement. No official support or endorsement by the PMDA is intended
More informationONE PART OF THE WHOLE: ANALYTICAL SIMILARITY & TOTALITY OF EVIDENCE
ONE PART OF THE WHOLE: ANALYTICAL SIMILARITY & TOTALITY OF EVIDENCE KATHERINE GIACOLETTI MIDWEST BIOPHARMACEUTICAL STATISTICS WORKSHOP, MAY 14-16 2018 INDIANAPOLIS, IN AGENDA Regulatory framework for biosimilarity
More informationSample Size and Power Calculation for High Order Crossover Designs
Sample Size and Power Calculation for High Order Crossover Designs Roger P. Qu, Ph.D Department of Biostatistics Forest Research Institute, New York, NY, USA 1. Introduction Sample size and power calculation
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationIntroduction to the Design and Evaluation of Group Sequential
SSCR ntroduction to the Design and Evaluation of Group Sequential Session 1 - Scientific Setting and mplications Presented July 27, 2016 Daniel L. Gillen Department of Statistics University of California,
More informationDose Exposure Response Relationships: the Basis of Effective Dose-Regimen Selection
Dose Exposure Response Relationships: the Basis of Effective Dose-Regimen Selection Model-Based Solutions to a Calibration Problem Michael Looby, Novartis Peter Milligan, Pfizer Dose Regimen Selection:
More informationScientific Advisory Groups (SAG)
Scientific Advisory Groups (SAG) Experience and impact of patient involvement Presented by: Francesco Pignatti Human Medicines Evaluation Division, EMA Training session for patients and consumers involved
More informationKey Multiplicity Issues in Clinical Trials. Alex Dmitrienko (Mediana Inc) Biopharmaceutical Section s webinar series, June 2017
Key Multiplicity Issues in Clinical Trials Alex Dmitrienko (Mediana Inc) Biopharmaceutical Section s webinar series, June 2017 Outline Key topics Overview of multiplicity issues in Phase III trials Traditional
More informationFormalizing Study Design & Writing Your Protocol. Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care
TWIST: Formalizing Study Design & Writing Your Protocol Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care Presented by the Joint Clinical Trials Office/Quality Assurance Unit
More informationBIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS CLINICAL PHASE Clinical Studies: Class of all scientific approaches to evaluate Disease Prevention,
More informationAn Introduction to Flexible Adaptive Designs
An Introduction to Flexible Adaptive Designs Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical Research
More informationBest practice in dose finding studies. Rudolf Koehne-Volland Head of Biostatistics & CEO Metronomia Clinical Research GmbH
Best practice in dose finding studies Rudolf Koehne-Volland Head of Biostatistics & CEO Metronomia Clinical Research GmbH Best practice s in dose 13-Oct-2016 finding 2 Best practice in dose finding studies
More informationShort Course: Adaptive Clinical Trials
Short Course: Adaptive Clinical Trials Presented at the 2 Annual Meeting of the Society for Clinical Trials Vancouver, Canada Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical
More informationAnna Mennenga, Grand Valley State University Monica Ahrens, University of Iowa Dr. Eric Foster, Assistant Professor (Clinical), Dept.
The Consequences of Cluster Randomization in Phase III Clinical Trial Interim Analyses Anna Mennenga, Grand Valley State University Monica Ahrens, University of Iowa Dr. Eric Foster, Assistant Professor
More informationClinical trial design issues and options for study of rare diseases
Clinical trial design issues and options for study of rare diseases November 3, 2016 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is coordinated
More informationDraft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September
23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis
More informationDiscussion. Design of Experiments in Healthcare, dose-ranging studies, astrophysics and other dangerous things
Discussion Design of Experiments in Healthcare, dose-ranging studies, astrophysics and other dangerous things 1 If you think bad, don t think much M.D. PhD. 2 Contopoulous-Ioannidis et al. Life Cycle of
More informationPackage ph2bayes. February 26, 2018
Package ph2bayes February 26, 2018 Type Package Title Bayesian Single-Arm Phase II Designs Version 0.0.2 An implementation of Bayesian singlearm phase II design methods for binary outcome based on posterior
More informationPredictive Modelling of Recruitment and Drug Supply in Multicenter Clinical Trials
Biopharmaceutical Section JSM 009 Predictive Modelling of Recruitment and Drug Supply in Multicenter Clinical Trials Vladimir Anisimov Abstract Patient recruitment and drug supply planning are the biggest
More informationA Modeling and Simulation Case Study
A Modeling and Simulation Case Study Impact on an Early Clinical Development Program Ken Kowalski, Steve Olson, Ann Remmers Pfizer Global Research and Development Ann Arbor, MI PAGE June 14-16, 16, 26
More informationGroup sequential designs for diagnostic accuracy studies
Group sequential designs for diagnostic accuracy studies Oke Gerke, Mie H Vilstrup, Ulrich Halekoh, Malene G Hildebrandt, PF Høilund Carlsen Workshop on flexible designs for diagnostic studies, UMC Göttingen,
More informationAdaptive Dose Ranging Studies:
Adaptive Dose Ranging Studies: Flexible, Adaptive Dose-Finding Designs Frank Bretz and José Pinheiro Novartis Pharmaceuticals Tokyo University of Science, July 28, 2006 Outline Background and motivation
More informationAcceptance of Foreign Clinical Data A U.S. Perspective
Acceptance of Foreign Clinical Data A U.S. Perspective Robert L. Justice, M.D., M.S. 9 th Kitasato University Harvard School of Public Health Symposium Disclaimer The views expressed in this presentation
More informationModels for Computer-Aided Trial & Program Design
Models for Computer-Aided Trial & Program Design Terrence Blaschke, M.D. VP, Methodology and Science Pharsight Corporation & Professor of Medicine & Molecular Pharmacology Stanford University MODELS What
More informationDichotomizing Continuous Biomarkers in the Co- Development of Drug and Companion Diagnostics: Practical Considerations
Dichotomizing Continuous Biomarkers in the Co- Development of Drug and Companion Diagnostics: Practical Considerations Liang Fang, Adarsh Joshi, Huan Wang, Yafeng Zhang Gilead Sciences, Inc. Co-Development
More informationSequential design approaches for bioequivalence studies with crossover designs. Pharmaceutical Statistics. (Potvin et al 2008: Pharm. Stat.
Sequential design approaches for bioequivalence studies with crossover designs. Pharmaceutical Statistics. (Potvin et al 2008: Pharm. Stat. 7:245 262) Additional results for Sequential design approaches
More informationRegulatory scene setting - benefits and risks of seamless Phase II / III trials
Safeguarding public health Regulatory scene setting - benefits and risks of seamless Phase II / III trials Rob Hemmings, Statistics Unit Manager MHRA, London December 2007 Definitions we are concerned
More informationAnalysis of Clinical Trials with Multiple Objectives
Analysis of Clinical Trials with Multiple Objectives Alex Dmitrienko (Mediana Inc) Regulatory Industry Statistics Workshop September 2017 Outline Regulatory guidelines FDA and EMA draft guidance documents
More informationCreation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
More informationAdaptive Design for Medical Device Development
Adaptive Design for Medical Device Development A guide to accelerate clinical development and enhance portfolio value Executive Summary In May 2015, the FDA released a draft guidance document regarding
More informationAdaptive Model-Based Designs in Clinical Drug Development. Vlad Dragalin Global Biostatistics and Programming Wyeth Research
Adaptive Model-Based Designs in Clinical Drug Development Vlad Dragalin Global Biostatistics and Programming Wyeth Research 2007 Rutgers Biostatistics Day February 16, 2007 Outline Definition and general
More informationElectronic Data Submission and Utilization in Japan
PharmaSUG SDE Japan 2018 Electronic Data Submission and Utilization in Japan Hiromi Sugano Biostatistics Reviewer Office of New Drug II / Office of Advanced Evaluation with Electronic Data Pharmaceuticals
More informationBOIN: A Novel Platform for Designing Early Phase Clinical Tri
BOIN: A Novel Platform for Designing Early Phase Clinical Trials Department of Biostatistics The University of Texas, MD Anderson Cancer Center Outline Introduction Bayesian optimal interval (BOIN) designs
More informationStatement on Regulatory Systems to Improve Pharmaceutical Safety
International Society for Pharmacoepidemiology (ISPE) Statement on Regulatory Systems to Improve Pharmaceutical Safety INTRODUCTION The public, some researchers, individual regulators and policymakers
More informationSummary of STREAM and Delamanid phase III trial results and implications:
Treating Patient, Not Disease: People-Centered Approach 7th TB Symposium Ministry of Health of the Kyrgyz Republic and Médecins Sans Frontières 1-2 March, 2018, BISHKEK, KYRGYZSTAN Summary of STREAM and
More informationBayesian Designs for Early Phase Clinical Trials
Bayesian Designs for Early Phase Clinical Trials Peter F. Thall, PhD Department of Biostatistics M.D. Anderson Cancer Center Fourteenth International Kidney Cancer Symposium Miami, Florida, November 6-7,
More informationAn Introduction to Clinical Research and Development
Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is
More informationNovel multiple testing procedures for structured study objectives and families of hypotheses a case study
Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Guenther Mueller-Velten Novartis Pharma AG EMA Workshop on Multiplicity Issues in Clinical Trials
More informationCancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents arxiv:1709.00918v3 [stat.me] 22 Aug 2018 José L. Jiménez 1, Mourad
More informationHow to implement the recently released EMA guideline on First-in-Human trials?
How to implement the recently released EMA guideline on First-in-Human trials? Academic Clinical Investigation Centers Perspective Pr D. DEPLANQUE National Coordinator of the French Clinical Investigation
More informationEvaluating dose-response under model uncertainty using several nested models
Evaluating dose-response under model uncertainty using several nested models Corine Baayen 1,2, Philip Hougaard 1 & Christian Pipper 2 1 H. Lundbeck A/S 2 University of Copenhagen October 2014 Baayen,
More informationMeta-analysis of clinical dose response in a large drug development portfolio
Meta-analysis of clinical dose response in a large drug development portfolio N. Thomas 1, K. Sweeney, and V. Somayaji 1 Pfizer Inc 445 Eastern Point Road Groton, CT 06340 ASA-NJ, June 2014 Thomas, Sweeney,
More informationDose Selection in Drug Development and Regulation: Possible Future Direction. Richard Lalonde and Donald Stanski Pfizer and AstraZeneca
Dose Selection in Drug Development and Regulation: Possible Future Direction Richard Lalonde and Donald Stanski Pfizer and AstraZeneca Overview What is the problem and how did we get here Examples of the
More informationNonparametric Stepwise Procedure for Identification of Minimum Effective Dose (MED)
International Journal of Statistics and Systems ISSN 097-675 Volume, Number (06), pp. 77-88 Research India Publications http://www.ripublication.com Nonparametric Stepwise Procedure for Identification
More informationCDER and CBER Experience
CDER and CBER Experience Lisa M. LaVange Director, Office of Biostatistics OTS, CDER, FDA ACDRS Special Workshop: Substantial Evidence in 21 st Century Regulatory Science UC-Washington Center April 21,
More informationMeta-analysis of clinical dose response in a large drug development portfolio
Meta-analysis of clinical dose response in a large drug development portfolio N. Thomas 1, K. Sweeney, and V. Somayaji 1 Pfizer Inc 445 Eastern Point Road Groton, CT 06340 BASS, 2013 Thomas, Sweeney, Somayaji
More informationBiostatistics for Public Health Practice
Biostatistics for Public Health Practice Week 03 3 Concepts of Statistical Inference Associate Professor Theo Niyonsenga HLTH 5187: Biostatistics for MPHP 1 Statistical Inference Statistics Survey Sampling
More informationEnrichment Design with Patient Population Augmentation
Enrichment Design with Patient Population Augmentation Subhead Calibri 14pt, White Bo Yang, AbbVie Yijie Zhou, AbbVie Lanju Zhang, AbbVie Lu Cui, AbbVie Author Disclosure Bo Yang is a former Employee of
More informationAccelerating Clinical Development With Adaptive Study Designs
Accelerating Clinical Development With Adaptive Study Designs Amit Roy Discovery Medicine & Clinical Pharmacology Bristol-Myers Squibb KRPIA Regulatory Committee Annual Symposium Seoul November 23, 2007
More informationPOPULATION ENRICHMENT DESIGNS FOR ADAPTIVE CLINICAL TRIALS. An Aptiv Solutions White Paper
FOR ADAPTIVE CLINICAL TRIALS An Aptiv Solutions White Paper EXECUTIVE SUMMARY The increasing pressure on governments caused by the spiraling healthcare costs is leading to a growing demand by payers for
More informationThe Role of Adaptive Designs in Clinical Development Program*
The Role of Adaptive Designs in Clinical Development Program* Sue-Jane Wang, Ph.D. Associate Director, Adaptive Design and Pharmacogenomics Office of Biostatistics, Office of Translational Sciences Center
More informationCombining Phase IIb and Phase III. Clinical Trials. Christopher Jennison. Partnerships in Clinical Trials,
Combining Phase IIb and Phase III Clinical Trials Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Partnerships in Clinical Trials, Brussels,
More informationTwenty-five years of confirmatory adaptive designs: opportunities and pitfalls
Featured Article Received 2 September 2014, Accepted 19 February 2015 Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.6472 Twenty-five years of confirmatory adaptive
More informationOPC. The Use of Objective Performance Criteria in Medical Device Trials: An Industry perspective. David Breiter Boston Scientific CRM
OPC The Use of Objective Performance Criteria in Medical Device Trials: An Industry perspective David Breiter Boston Scientific CRM FDA/Industry Workshop, 2006 1 Outline What is an OPC Trial designs, benefits,
More informationFuture directions of benefit-risk assessment in Europe
Future directions of benefit-risk assessment in Europe ISPE Mid-year meeting, Munich, Germany 12 th April 2013 Presented by: Deborah Ashby Imperial College London Outline Challenges in medical decision-making
More informationNon-parametric optimal design in dose finding studies
Biostatistics (2002), 3, 1,pp. 51 56 Printed in Great Britain Non-parametric optimal design in dose finding studies JOHN O QUIGLEY Department of Mathematics, University of California, San Diego, CA 92093,
More informationStatistical signal detection in Clinical Trial data
Statistical signal detection in Clinical Trial data Andreas Brueckner Christiane Ahlers, Anngret Mallick, Nils Opitz, Vlasta Pinkston, Bruno Tran, Janet Scott, Harry Southworth, Bruno Tran, Lionel Van
More informationBayesian Approaches to Phase I Clinical Trials:
Bayesian Approaches to Phase I Clinical Trials: Methodological and Practical Aspects Design of Experiments in Healthcare Isaac Newton Institue of Mathematical Sciences August 2011, Cambridge UK Beat Neuenschwander
More informationAdaptive Trials. Raphaël Porcher. CRESS, Inserm UMR-S 1153, Université Paris Descartes
Adaptive Trials Raphaël Porcher CRESS, Inserm UMR-S 1153, Université Paris Descartes Modélisation et simulation d essais cliniques Toulouse 9 10 avril 2015 R. Porcher (CRESS U1153) 1 / 69 Outline Outline
More informationSample size Re estimation and Bias
Sample size Re estimation and Bias Medical University of Vienna, January 4, 03 Frank Miller, Stockholm University, Sweden Partly joint work with Tim Friede, Dept. of Medical Statistics, University Medical
More informationFriday, September 12th, :00-11:00 am New Research Building Auditorium Refreshments will be provided at 9:45am. Gang Han, Ph.D.
Friday, September 12th, 2014 10:00-11:00 am New Research Building Auditorium Gang Han, Ph.D. Associate Research Scientist in Public Health (Biostatistics) School of Public Health, Yale Center for Analytical
More informationAn Adaptive Oncology Dose Finding Trial Using the Time-to-Event Continual Reassessment Method Incorporating Cycle Information
An Adaptive Oncology Dose Finding Trial Using the Time-to-Event Continual Reassessment Method Incorporating Cycle Information Bo Huang, PhD Oncology Business Unit Pfizer Inc. PhRMA KOL Adaptive Design
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More informationGuiding dose escalation studies in Phase 1 with unblinded modeling
Guiding dose escalation studies in Phase 1 with unblinded modeling Andreas Krause Lead Scientist Modeling & Simulation Andreas.Krause@idorsia.com Basel Biometrics Section (BBS) Seminar: Innovative model-based
More informationPediatric Exclusivity and Drug Development Requirements in the Overall Pediatric Population. Prepared by Beckloff Associates, Inc.
and Drug Development Requirements in the Overall Pediatric Population 1 INTRODUCTION AND OVERVIEW Prepared by Beckloff Associates, Inc. Although children suffer from many of the same diseases as adults
More information